2007, Best practice & research., ISBN 0702029564, Volume 21, no. 5., 805-967
Book
Clinical and experimental rheumatology, ISSN 0392-856X, 2014, Volume 32, Issue 5, pp. S-65 - 74
In rheumatoid arthritis, disease activity cannot be measured using a single variable. The Disease Activity Score (DAS) has been developed as a quantitative...
DAS28 | DAS | Disease activity score | RESPONSE CRITERIA | FUNCTIONAL-CAPACITY | AMERICAN-COLLEGE | RANDOMIZED CONTROLLED-TRIAL | RHEUMATOLOGY | IMPROVEMENT CRITERIA | COLLEGE-OF-RHEUMATOLOGY | COMPOSITE INDEXES | PRELIMINARY REMISSION CRITERIA | ARTHRITIS PATIENTS | CLINICAL-PRACTICE | disease activity score
DAS28 | DAS | Disease activity score | RESPONSE CRITERIA | FUNCTIONAL-CAPACITY | AMERICAN-COLLEGE | RANDOMIZED CONTROLLED-TRIAL | RHEUMATOLOGY | IMPROVEMENT CRITERIA | COLLEGE-OF-RHEUMATOLOGY | COMPOSITE INDEXES | PRELIMINARY REMISSION CRITERIA | ARTHRITIS PATIENTS | CLINICAL-PRACTICE | disease activity score
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2010, Volume 69, Issue 6, pp. 1022 - 1028
Background There is a need for biomarkers that can predict anti-tumour necrosis factor (anti-TNF) treatment outcome in patients with rheumatoid arthritis (RA)....
Journal Article
Arthritis care & research, ISSN 2151-464X, 04/2018, Volume 70, Issue 4, pp. 516 - 524
Objective: To determine the impact of stopping tumor necrosis factor inhibitor (TNFi) treatment on patient-reported outcomes (PROs) of physical and mental...
Rheumatology | UT-Hybrid-D
Rheumatology | UT-Hybrid-D
Journal Article
Best Practice & Research Clinical Rheumatology, ISSN 1521-6942, 2016, Volume 30, Issue 5, pp. 787 - 788
Journal Article
Clinical and Experimental Rheumatology, ISSN 0392-856X, 01/2011, Volume 29, Issue 1, pp. 26 - 34
Objectives To evaluate prevalence of dose escalation among RA patients in normal clinical practice treated with etanercept, adalimumab or infliximab and to...
Dose escalation | Etanercept | Infliximab | Adalimumab | Rheumatoid arthritis | TNF-α inhibitor | RHEUMATOID-ARTHRITIS | CONCOMITANT METHOTREXATE | etanercept | infliximab | MONOCLONAL-ANTIBODY | ANKYLOSING-SPONDYLITIS | DRUG-RESISTANCE | RETENTION RATES | RHEUMATOLOGY | rheumatoid arthritis | ANTITUMOR NECROSIS FACTOR | adalimumab | dose escalation | THERAPY | TNF-alpha inhibitor | Severity of Illness Index | Drug Administration Schedule | Antirheumatic Agents - administration & dosage | Humans | Middle Aged | Male | Receptors, Tumor Necrosis Factor - administration & dosage | Immunoglobulin G - administration & dosage | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized | Drug Dosage Calculations | Antibodies, Monoclonal - administration & dosage | Arthritis, Rheumatoid - drug therapy | Female | Health Status | Arthritis, Rheumatoid - physiopathology | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Antirheumatic Agents - therapeutic use
Dose escalation | Etanercept | Infliximab | Adalimumab | Rheumatoid arthritis | TNF-α inhibitor | RHEUMATOID-ARTHRITIS | CONCOMITANT METHOTREXATE | etanercept | infliximab | MONOCLONAL-ANTIBODY | ANKYLOSING-SPONDYLITIS | DRUG-RESISTANCE | RETENTION RATES | RHEUMATOLOGY | rheumatoid arthritis | ANTITUMOR NECROSIS FACTOR | adalimumab | dose escalation | THERAPY | TNF-alpha inhibitor | Severity of Illness Index | Drug Administration Schedule | Antirheumatic Agents - administration & dosage | Humans | Middle Aged | Male | Receptors, Tumor Necrosis Factor - administration & dosage | Immunoglobulin G - administration & dosage | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized | Drug Dosage Calculations | Antibodies, Monoclonal - administration & dosage | Arthritis, Rheumatoid - drug therapy | Female | Health Status | Arthritis, Rheumatoid - physiopathology | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Antirheumatic Agents - therapeutic use
Journal Article
Patient education and counseling, ISSN 0738-3991, 01/2018, Volume 101, Issue 1, pp. 67 - 73
Objective: To develop a Disease and treatment associated Knowledge in RA item bank (DataK-RA) based on item response theory. Methods: Initial items were...
Measurement instrument | (Patient) education | Personalized healthcare | Item response theory | Rheumatoid arthritis | Item bank | (Patient) knowledge | Quality indicator
Measurement instrument | (Patient) education | Personalized healthcare | Item response theory | Rheumatoid arthritis | Item bank | (Patient) knowledge | Quality indicator
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 03/2014, Volume 73, Issue 3, pp. 492 - 509
In this article, the 2010 European League against Rheumatism (EULAR) recommendations for the management of rheumatoid arthritis (RA) with synthetic and...
DMARDs (biologic) | Rheumatoid Arthritis | Early Rheumatoid Arthritis | COMBINATION THERAPY | JOINT DAMAGE | INADEQUATE RESPONSE | FOLLOW-UP | RHEUMATOLOGY | ADALIMUMAB PLUS METHOTREXATE | RAPID RADIOGRAPHIC PROGRESSION | LOW-DOSE PREDNISOLONE | DMARDs (synthetic) | Treatment | TREATMENT STRATEGIES | PARALLEL-GROUP | DOUBLE-BLIND | Evidence-Based Medicine - methods | Glucocorticoids - therapeutic use | Algorithms | Arthritis, Rheumatoid - drug therapy | Humans | Immunosuppressive Agents - therapeutic use | Drug Therapy, Combination | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Antirheumatic Agents - therapeutic use | Biological Products - therapeutic use | Usage | Care and treatment | Antirheumatic agents | Rheumatoid arthritis | Therapeutics | Methods | Homeopathy | Materia medica and therapeutics | Task forces | Infectious diseases | Biological products | Rheumatology | Gangrene | Rheumatism | Tumor necrosis factor-TNF | TNF inhibitors | Agreements | Clinical medicine | Patients | 1506 | Recommendation
DMARDs (biologic) | Rheumatoid Arthritis | Early Rheumatoid Arthritis | COMBINATION THERAPY | JOINT DAMAGE | INADEQUATE RESPONSE | FOLLOW-UP | RHEUMATOLOGY | ADALIMUMAB PLUS METHOTREXATE | RAPID RADIOGRAPHIC PROGRESSION | LOW-DOSE PREDNISOLONE | DMARDs (synthetic) | Treatment | TREATMENT STRATEGIES | PARALLEL-GROUP | DOUBLE-BLIND | Evidence-Based Medicine - methods | Glucocorticoids - therapeutic use | Algorithms | Arthritis, Rheumatoid - drug therapy | Humans | Immunosuppressive Agents - therapeutic use | Drug Therapy, Combination | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Antirheumatic Agents - therapeutic use | Biological Products - therapeutic use | Usage | Care and treatment | Antirheumatic agents | Rheumatoid arthritis | Therapeutics | Methods | Homeopathy | Materia medica and therapeutics | Task forces | Infectious diseases | Biological products | Rheumatology | Gangrene | Rheumatism | Tumor necrosis factor-TNF | TNF inhibitors | Agreements | Clinical medicine | Patients | 1506 | Recommendation
Journal Article
Canadian Journal of Cardiology, ISSN 0828-282X, 2013, Volume 29, Issue 5, pp. 639.e13 - 639.e13
Cardiovascular | CARDIAC & CARDIOVASCULAR SYSTEMS | Captopril - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Arthritis, Rheumatoid - drug therapy | Humans | Hypertension - complications | Hypertension - drug therapy | Antihypertensive Agents - therapeutic use | Arthritis, Rheumatoid - complications
Journal Article
Nature, ISSN 0028-0836, 2014, Volume 506, Issue 7488, pp. 376 - +
A major challenge in human genetics is to devise a systematic strategy to integrate disease-associated variants with diverse genomic and biological data sets...
RECEPTOR INHIBITION | VARIANTS | MULTIDISCIPLINARY SCIENCES | DISEASE | SUSCEPTIBILITY | RISK | LOCI | IDENTIFICATION | TRAITS | GENOME-WIDE ASSOCIATION | RESOURCE | European Continental Ancestry Group - genetics | Genetic Predisposition to Disease - genetics | Genome-Wide Association Study | Humans | Asian Continental Ancestry Group - genetics | Computational Biology | Male | Drug Repositioning | Molecular Targeted Therapy | Drug Discovery | Case-Control Studies | Arthritis, Rheumatoid - pathology | Mice, Knockout | Arthritis, Rheumatoid - metabolism | Arthritis, Rheumatoid - genetics | Animals | Arthritis, Rheumatoid - drug therapy | Alleles | Polymorphism, Single Nucleotide - genetics | Female | Hematologic Neoplasms - genetics | Mice | Hematologic Neoplasms - metabolism | Quantitative trait loci | Genome-wide association studies | Rheumatoid arthritis | Genetic research | Genetic aspects | Research | Human genetics | Disease | Hematology | Cytokines | Genes | Genomics | Genomes | Meta-analysis | Proteins | Confidence intervals | Hypotheses | Quality control | Epigenetics | Population | Genetics | Health risk assessment | Asians | Cancer | Index Medicus | Rheumatology and Autoimmunity | Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Reumatologi och inflammation | Virtual screening | Klinisk medicin
RECEPTOR INHIBITION | VARIANTS | MULTIDISCIPLINARY SCIENCES | DISEASE | SUSCEPTIBILITY | RISK | LOCI | IDENTIFICATION | TRAITS | GENOME-WIDE ASSOCIATION | RESOURCE | European Continental Ancestry Group - genetics | Genetic Predisposition to Disease - genetics | Genome-Wide Association Study | Humans | Asian Continental Ancestry Group - genetics | Computational Biology | Male | Drug Repositioning | Molecular Targeted Therapy | Drug Discovery | Case-Control Studies | Arthritis, Rheumatoid - pathology | Mice, Knockout | Arthritis, Rheumatoid - metabolism | Arthritis, Rheumatoid - genetics | Animals | Arthritis, Rheumatoid - drug therapy | Alleles | Polymorphism, Single Nucleotide - genetics | Female | Hematologic Neoplasms - genetics | Mice | Hematologic Neoplasms - metabolism | Quantitative trait loci | Genome-wide association studies | Rheumatoid arthritis | Genetic research | Genetic aspects | Research | Human genetics | Disease | Hematology | Cytokines | Genes | Genomics | Genomes | Meta-analysis | Proteins | Confidence intervals | Hypotheses | Quality control | Epigenetics | Population | Genetics | Health risk assessment | Asians | Cancer | Index Medicus | Rheumatology and Autoimmunity | Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Reumatologi och inflammation | Virtual screening | Klinisk medicin
Journal Article
Annals of the rheumatic diseases, ISSN 0003-4967, 2013, Volume 72, Issue 12, pp. 2050 - 2051
The Health Assessment Questionnaire (HAQ) Disability Index is the most frequently used and validated measure of physical function for patients with rheumatoid...
METIS-298500 | IR-87638
METIS-298500 | IR-87638
Journal Article
Rheumatic Disease Clinics of North America, ISSN 0889-857X, 11/2009, Volume 35, Issue 4, pp. 745 - 757
The Disease Activity Score (DAS), its modified version the DAS28, and the DAS-based European League Against Rheumatism (EULAR) response criteria are well-known...
EULAR | Disease Activity Score | Rheumatoid arthritis | Response criteria | ORIGINAL DAS | FUNCTIONAL-CAPACITY | RHEUMATOLOGY | IMPROVEMENT CRITERIA | ROUTINE ASSESSMENT | ARTHRITIS | COLLEGE-OF-RHEUMATOLOGY | COMPOSITE INDEXES | OUTCOME MEASURES | CLINICAL-PRACTICE | VALIDITY | Disability Evaluation | Severity of Illness Index | Health Status | Arthritis, Rheumatoid - diagnosis | Humans | Arthritis, Rheumatoid - physiopathology
EULAR | Disease Activity Score | Rheumatoid arthritis | Response criteria | ORIGINAL DAS | FUNCTIONAL-CAPACITY | RHEUMATOLOGY | IMPROVEMENT CRITERIA | ROUTINE ASSESSMENT | ARTHRITIS | COLLEGE-OF-RHEUMATOLOGY | COMPOSITE INDEXES | OUTCOME MEASURES | CLINICAL-PRACTICE | VALIDITY | Disability Evaluation | Severity of Illness Index | Health Status | Arthritis, Rheumatoid - diagnosis | Humans | Arthritis, Rheumatoid - physiopathology
Journal Article
PharmacoEconomics, ISSN 1170-7690, 2014, Volume 32, Issue 10, pp. 1015 - 1028
Background Management of rheumatoid arthritis (RA) is characterised by a sequence of disease-modifying antirheumatic drugs (DMARDs) and biological response...
IR-93064 | METIS-307008
IR-93064 | METIS-307008
Journal Article
Rheumatology, ISSN 1462-0324, 2015, Volume 54, Issue 6, pp. 1074 - 1079
Objective. Under the auspices of the European League Against Rheumatism (EULAR), a study group of investigators representing European biologic DMARD (bDMARD)...
IR-96771 | METIS-311187
IR-96771 | METIS-311187
Journal Article
Nature Reviews. Rheumatology, ISSN 1759-4790, 2011, Volume 7, Issue 5, pp. 260 - 261
RHEUMATOLOGY | DISEASE-ACTIVITY | Disability Evaluation | Bone and Bones - pathology | Cartilage - pathology | Humans | Joints - pathology | Adrenal Cortex Hormones - therapeutic use | Cartilage - physiopathology | Joints - physiopathology | Arthritis, Rheumatoid - pathology | Bone and Bones - physiopathology | Arthritis, Rheumatoid - drug therapy | Arthrography | Arthritis, Rheumatoid - physiopathology
Journal Article
Journal of Rheumatology, ISSN 0315-162X, 03/2004, Volume 31, Issue 69, pp. 14 - 21
Rheumatoid arthritis is a heterogeneous chronic disease with an unpredictable disease course. To study such a disease, longterm observational studies are...
Outcome and process assessment | Rheumatoid arthritis | Cohort studies | RADIOGRAPHS | VALIDATION | FOLLOW-UP | RHEUMATOLOGY | IMPROVEMENT CRITERIA | rheumatoid arthritis | SHARP METHOD | outcome and process assessment | cohort studies | VALIDITY | ASSOCIATION | ONSET | PROGRESSION | DISEASE-ACTIVITY SCORE
Outcome and process assessment | Rheumatoid arthritis | Cohort studies | RADIOGRAPHS | VALIDATION | FOLLOW-UP | RHEUMATOLOGY | IMPROVEMENT CRITERIA | rheumatoid arthritis | SHARP METHOD | outcome and process assessment | cohort studies | VALIDITY | ASSOCIATION | ONSET | PROGRESSION | DISEASE-ACTIVITY SCORE
Journal Article
Nature genetics, ISSN 1061-4036, 2010, Volume 42, Issue 6, pp. 508 - U56
To identify new genetic risk factors for rheumatoid arthritis, we conducted a genome-wide association study meta-analysis of 5,539 autoantibody-positive...
SYSTEMIC-LUPUS-ERYTHEMATOSUS | POLYMORPHISMS | REPLICATION | VARIANTS | GENE | GENETICS & HEREDITY | SUSCEPTIBILITY LOCI | CONFIRMATION | COMMON | CELIAC-DISEASE | REGION | Arthritis, Rheumatoid - genetics | Genetic Predisposition to Disease | Genome-Wide Association Study | Humans | Risk Factors | Autoantibodies - administration & dosage | Polymorphism, Single Nucleotide | Genetic Loci | Genetic aspects | Diagnosis | Research | Single nucleotide polymorphisms | Rheumatoid arthritis | Risk factors | Studies | Medical research | Genotype & phenotype | Health sciences | Biomedical research | Heart attacks | Arthritis | Gene loci | Grants | Meta-analysis
SYSTEMIC-LUPUS-ERYTHEMATOSUS | POLYMORPHISMS | REPLICATION | VARIANTS | GENE | GENETICS & HEREDITY | SUSCEPTIBILITY LOCI | CONFIRMATION | COMMON | CELIAC-DISEASE | REGION | Arthritis, Rheumatoid - genetics | Genetic Predisposition to Disease | Genome-Wide Association Study | Humans | Risk Factors | Autoantibodies - administration & dosage | Polymorphism, Single Nucleotide | Genetic Loci | Genetic aspects | Diagnosis | Research | Single nucleotide polymorphisms | Rheumatoid arthritis | Risk factors | Studies | Medical research | Genotype & phenotype | Health sciences | Biomedical research | Heart attacks | Arthritis | Gene loci | Grants | Meta-analysis
Journal Article